Canada · Delayed Price · Currency is CAD Savaria Earnings Call Transcripts
Fiscal Year 2025
-
Record Q4 and full-year results driven by strong growth in accessibility and patient care, with significant margin expansion and operational improvements from Savaria One. Strategic acquisitions, capacity expansion, and a robust pipeline position the company for continued growth in 2026 and beyond.
-
Record Q3 results with 21.2% adjusted EBITDA margin and 5.2% revenue growth, driven by operational improvements and strong Accessibility segment performance. Guidance for annual revenue and margins remains robust, with continued focus on growth, disciplined capital allocation, and strategic expansion.
-
Record Q2 margins and EBITDA were driven by operational efficiencies and new product launches, with revenue up 2.4% year-over-year. Guidance for 2025 remains strong, supported by a robust backlog, improved leverage, and ongoing strategic investments.
-
Record Q1 results with EBITDA up 17% and margin at 18.5%, driven by strong North American growth and operational improvements. Guidance for 2025 is maintained amid tariff uncertainty, with a robust backlog and new product launches supporting future performance.
Fiscal Year 2024
-
Q4 and 2024 results met expectations, with strong Patient Care growth and improved margins. 2025 guidance reflects tariff-related uncertainty, but management is confident in long-term margin recovery and growth, supported by operational improvements and a robust balance sheet.
-
Q3 saw record profitability with Adjusted EBITDA margin at 19.5% and strong North American growth, while Europe focused on margin gains. Cash flow and deleveraging improved, supporting future acquisitions and product launches.
-
Q2 2024 saw record revenue, gross profit, and Adjusted EBITDA, driven by double-digit organic growth in accessibility and strong operational execution. The company is on track for its 2025 targets, with healthy backlogs and ongoing margin improvements, especially in Europe.